Predict your next investment

Aptar Pharma company logo
Corporation
HEALTHCARE | Drug Delivery
aptar.com/pharmaceutical

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Partners & Customers

10

About Aptar Pharma

Aptar Pharma is the AptarGroup business segment dedicated to the healthcare industry. The company focuses on drug delivery.

Aptar Pharma Headquarter Location

Crystal Lake, Illinois,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Aptar Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aptar Pharma Rank

Research containing Aptar Pharma

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Aptar Pharma in 1 CB Insights research brief, most recently on May 6, 2021.

Latest Aptar Pharma News

Aptar acquires worldwide license for dry powder inhaler

Aug 8, 2022

Aptar Pharma, a global provider in drug delivery and active material science solutions, has acquired the worldwide rights to clinical stage drug developer Pharmaxis’ Orbital inhaler, a device designed to deliver high payload dry powder to the lungs.

Aptar Pharma Investments

2 Investments

Aptar Pharma has made 2 investments. Their latest investment was in TerraCycle as part of their Series A on December 12, 2020.

CBI Logo

Aptar Pharma Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/8/2020

Series A

TerraCycle

$25M

Yes

19

5/30/2018

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/8/2020

5/30/2018

Round

Series A

Series D

Company

TerraCycle

Subscribe to see more

Amount

$25M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

19

10

Aptar Pharma Portfolio Exits

1 Portfolio Exit

Aptar Pharma has 1 portfolio exit. Their latest portfolio exit was Propeller Health on December 03, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/3/2018

Acquired

$99M

9

Date

12/3/2018

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

9

Aptar Pharma Acquisitions

1 Acquisition

Aptar Pharma acquired 1 company. Their latest acquisition was Cohero Health on November 04, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/4/2020

Debt

$99M

$15.6M

Acquired

1

Date

11/4/2020

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$15.6M

Note

Acquired

Sources

1

Aptar Pharma Partners & Customers

10 Partners and customers

Aptar Pharma has 10 strategic partners and customers. Aptar Pharma recently partnered with Opiant on June 6, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

6/8/2022

Partner

United States

1

10/26/2021

Partner

United Kingdom

Stallergenes Greer and Aptar Pharma Announce Partnership to Develop Novel Connected Device for Allergen Immunotherapy Treatment Delivery

`` This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer Ltd 's investments in innovation to provide a large range of precise personalised allergen immunotherapy options adapted to the individual needs and lifestyle of patients .

4

8/17/2021

Licensor

Australia

Aptar Pharma, Pharmaxis Enter Orbital DPI Agreement

Howard Burnett , Vice President Global Pulmonary Category , Aptar Pharma said , `` We are pleased to partner with Pharmaxis on this novel technology , which continues the development of Aptar Pharma 's industry-leading portfolio of devices for inhalation .

3

4/27/2021

Vendor

Norway

Subscribe to see more

Subscribe to see more

10

4/6/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

6/8/2022

10/26/2021

8/17/2021

4/27/2021

4/6/2021

Type

Partner

Partner

Licensor

Vendor

Partner

Business Partner

Country

United States

United Kingdom

Australia

Norway

United States

News Snippet

Stallergenes Greer and Aptar Pharma Announce Partnership to Develop Novel Connected Device for Allergen Immunotherapy Treatment Delivery

`` This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer Ltd 's investments in innovation to provide a large range of precise personalised allergen immunotherapy options adapted to the individual needs and lifestyle of patients .

Aptar Pharma, Pharmaxis Enter Orbital DPI Agreement

Howard Burnett , Vice President Global Pulmonary Category , Aptar Pharma said , `` We are pleased to partner with Pharmaxis on this novel technology , which continues the development of Aptar Pharma 's industry-leading portfolio of devices for inhalation .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

4

3

10

10

Aptar Pharma Team

1 Team Member

Aptar Pharma has 1 team member, including current President, Jerome Magniet.

Name

Work History

Title

Status

Jerome Magniet

President

Current

Name

Jerome Magniet

Work History

Title

President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.